Business Context and Reporting Period
Company: AMC Entertainment Holdings, Inc. (AMCH)
Filing Type: Form 8-K (Current Report)
Date of Report: March 3, 2016
Event: Entry into a Material Definitive Agreement to acquire Carmike Cinemas, Inc. (Carmike).
Key Financial Metrics and Transaction Terms
This filing details a merger agreement rather than periodic financial results. Key financial terms include:
- Merger Consideration: $30.00 in cash per share of Carmike common stock.
- Financing Commitment: Citigroup Global Markets Inc. committed to provide:
- Senior secured incremental term loan: Up to $560.0 million.
- Senior subordinated bridge loan: Up to $300.0 million.
- Termination Fees:
- $30 million: Payable by Carmike to AMCH if Carmike changes its recommendation or enters a superior transaction.
- $50 million: Payable by AMCH to Carmike if the deal fails due to regulatory injunctions, failure to close by the end date (subject to extensions), or material breach of antitrust covenants.
Note: The filing text does not provide current revenue, profit, cash flow, or debt levels for AMCH or Carmike.
Material Changes and Transaction Structure
AMCH, through its subsidiary Congress Merger Subsidiary, Inc., will merge with and into Carmike. Carmike will become an indirect, wholly-owned subsidiary of AMCH. The transaction is not subject to a financing condition but requires:
- Approval by Carmike stockholders.
- Antitrust approval and expiration of Hart-Scott-Rodino (HSR) waiting periods.
- Absence of a material adverse effect on Carmike.
- Absence of dissenters' rights exercised by holders of 20% or more of Carmike stock.
AMCH has agreed to negotiate divestitures if required for antitrust approval, with limits on cash flow loss ($25 million) and net book value ($20 million) for non-theatre assets.
Guidance, Outlook, and Risks
Outlook: The parties intend to use reasonable best efforts to consummate the merger. AMCH expects to seek long-term debt financing to replace the bridge loan, subject to market conditions.
Risks and Contingencies:
- Regulatory Risk: Failure to obtain antitrust approval or receiving unfavorable conditions.
- Financing Risk: Inability to secure long-term financing on acceptable terms.
- Integration Risk: Challenges in realizing synergies, managing a two-brand strategy, and maintaining relationships with customers and suppliers.
- Termination Risk: The deal may not close by the December 5, 2016 end date (subject to a 90-day extension), potentially triggering termination fees.
- Indebtedness: Increased leverage from the acquisition financing.
Investor Verification Checklist
- Verify the total transaction value based on Carmike's outstanding share count and the $30.00 per share price.
- Confirm the status of regulatory approvals (HSR Act and antitrust) and any potential divestiture requirements.
- Review the terms of the Debt Commitment Letter (Exhibit 10.1) for interest rates, covenants, and conditions precedent.
- Monitor the timeline for the Carmike stockholder vote and the December 5, 2016 termination deadline.
- Assess the impact of the $860 million in committed debt on AMCH's existing leverage ratios and liquidity.